Washington University Radiation Oncology faculty and staff have recently returned from the 37th Congress of the European Society for Therapeutic Radiation Oncology (ESTRO), held in late April in Barcelona, Spain.
Jeffrey Bradley, MD, a Washington University radiation oncologist at Siteman Cancer Center, participated in a lung cancer symposium about radiation dose escalation where he presented a 5-year review of the results from the RTOG 0617 trial, which tested the use of high- versus standard-dose radiotherapy for unresectable stage III non-small cell lung cancer, and the five subsequently published secondary analyses. Geoffrey Hugo, PhD, a Washington University medical physicist at Siteman Cancer Center, presented on the first in-human images acquired on a new linear accelerator prototype with CT imaging capabilities that has recently been installed at Washington University. Clinical resident Amar Srivastava’s abstract, “Early PD-1 blockade improves disease control for NSCLC brain metastases treated with radiosurgery” discussed a retrospective study that showed patients with non-small cell lung cancer brain metastases may have improved outcomes when immunotherapy with PD-1 inhibitors is used concurrently with stereotactic radiosurgery.
Erin Wittland, a radiation therapist from Barnes-Jewish Hospital working with Washington University Radiation Oncology at Siteman Cancer Center, presented at a pre-congress educational session that provided attendees with an overview of magnetic resonance imaging (MRI) and its implementation in a clinical radiotherapy practice. Her presentation discussed the department’s experience implementing a clinical workflow for MRI-guided radiotherapy, and the day-to-day clinical processes that have been developed over the last four years, including adaptive radiotherapy and real-time MR-gated treatments.